Showing results (21-30 of 27) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2010
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trialHans Theodor Eich, Volker Diehl, Helen Görgen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study GroupPeter Borchmann, Heinz Haverkamp, Volker Diehl, et al.Hematological Oncology|October 31, 2017
Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphomaPavel Klener, Eva Fronkova, David Belada, et al.Lancet (London, England)|April 7, 2012
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trialAndreas Engert, Heinz Haverkamp, Carsten Kobe, et al.The Lancet. Haematology|May 28, 2021
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trialStefanie Kreissl, Helen Goergen, Ina Buehnen, et al.Lancet (London, England)|December 26, 2014
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trialKarolin Behringer, Helen Goergen, Felicitas Hitz, et al.Lancet (London, England)|October 25, 2017
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study GroupPeter Borchmann, Helen Goergen, Carsten Kobe, et al.Pageof 3